ConvaTec Group (LON:CTEC) Rating Reiterated by Barclays

ConvaTec Group (LON:CTECGet Rating)‘s stock had its “overweight” rating restated by investment analysts at Barclays in a research note issued on Monday, reports. They currently have a GBX 285 ($3.45) price target on the stock. Barclays‘s target price indicates a potential upside of 26.67% from the company’s current price.

Several other brokerages have also issued reports on CTEC. Royal Bank of Canada upgraded ConvaTec Group to a “sector perform” rating and increased their price target for the stock from GBX 195 ($2.36) to GBX 210 ($2.54) in a report on Wednesday, May 18th. JPMorgan Chase & Co. lifted their price target on ConvaTec Group from GBX 230 ($2.79) to GBX 255 ($3.09) and gave the stock an “overweight” rating in a report on Monday, June 27th. Finally, Berenberg Bank reiterated a “buy” rating and set a GBX 250 ($3.03) price target on shares of ConvaTec Group in a report on Wednesday, May 18th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of GBX 241.67 ($2.93).

Shares of CTEC stock opened at GBX 225 ($2.72) on Monday. The stock has a 50-day moving average of GBX 214.80 and a 200-day moving average of GBX 199.64. ConvaTec Group has a 1-year low of GBX 165.30 ($2.00) and a 1-year high of GBX 265 ($3.21). The stock has a market cap of £4.59 billion and a price-to-earnings ratio of 4,500.00. The company has a current ratio of 1.95, a quick ratio of 1.34 and a debt-to-equity ratio of 84.85.

In other ConvaTec Group news, insider Jonny Mason purchased 22,000 shares of the business’s stock in a transaction on Wednesday, May 18th. The stock was acquired at an average price of GBX 224 ($2.71) per share, for a total transaction of £49,280 ($59,675.47).

ConvaTec Group Company Profile (Get Rating)

ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes.

Read More

Analyst Recommendations for ConvaTec Group (LON:CTEC)

Receive News & Ratings for ConvaTec Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConvaTec Group and related companies with's FREE daily email newsletter.